Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dialysis Patients' heart risk: a new prediction model under study

NCT ID NCT07769190

Knowledge-focused Sponsor: Huashan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This study follows adults receiving maintenance hemodialysis for end-stage kidney disease to develop a model that predicts the risk of dying from cardiovascular disease. Researchers will track routine lab results, including how often blood phosphate levels stay in a target range, and whether patients undergo parathyroidectomy. The goal is to identify factors linked to heart-related death and build a risk prediction tool for this population.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a practical tool that helps doctors identify hemodialysis patients at higher risk of cardiovascular death, potentially guiding earlier or more personalized care.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The prediction model may not be accurate for all patients, and results may not apply beyond this specific group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

192 people

The number who actually took part.

Started

Jul 2021

Finished

Apr 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population comprises adults aged 18 to 85 years who have received maintenance hemodialysis for at least 3 months at the Hemodialysis Center of Huashan Hospital, Fudan University. Participants are selected according to the prespecified eligibility criteria and are observed under routine clinical care without a study-assigned treatment.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Receipt of maintenance hemodialysis for at least 3 months. 2. Adequate ability to understand the study and communicate with the investigators. 3. Provision of written informed consent. Exclusion Criteria: 1. Age younger than 18 years or older than 85 years. 2. Pregnancy or plans to become pregnant during the relevant study period. 3. Participation in another clinical research study within the preceding month. 4. Presence of a disease or clinical condition considered likely to materially affect serum phosphate concentrations. 5. Any other condition that, in the investigator's judgment, makes participation inappropriate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder chronic kidney disease end stage renal failure secondary hyperparathyroidism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular disease End-stage kidney disease (ESKD) Secondary hyperparathyroidism (SHPT)

Contacts and locations

Locations

  • Huashan hospital, Fudan university

    Shanghai, Shanghai Municipality, 200040, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.